Chadi Nabhan

Publications (70) View all

• Article: Diffuse large B-cell non-Hodgkin lymphoma in the very elderly: challenges and solutions.

  Shadi Latta, Peter H Cygan, Walter Fried, Chadi Nabhan
  [show abstract] [hide abstract]
  ABSTRACT: Diffuse large B-cell non-Hodgkin lymphoma (DLBCL) is a disease of the elderly, but our current guidelines and treatment paradigms for this disease are based on studies that have mainly enrolled younger patients. Because the number of people living beyond the age of 80 increased by more than 250% between 1960 and 2000, and since it is expected that the population over the age of 75 will triple by 2030, understanding how these elderly patients should be treated is paramount to improving outcomes for this potentially curable lymphoma. In this review, we outline the scope of the problem; we define "the elderly" and identify challenges in assessing this patient population. We also summarize pivotal studies that have been conducted in these elderly patients and suggest an algorithm to aid clinicians in making treatment decisions when faced with DLBCL patients older than 80.
  Oncology (Williston Park, N.Y.) 02/2013; 27(2):126-30, 132-6, 138. · 1.03 Impact Factor
• Article: Autologous blood cell transplantation versus HLA-identical siblingtransplantation for acute myeloid leukemia in first complete remission:a registry study from the Center for International Blood and MarrowTransplantation Research.

  Armand Keating, Gisela Tunes da Silva, Waleska S Perez, Vikas Gupta, Corey S Cutler, Karen K Ballen, Mitchell S Cairo, Bruce M Camitta, Richard E Champlin, James L Gajewski, Hillard M Lazarus, Michael Lill, David I Marks, Chadi Nabhan, Gary J Schiller, Gerard Socie, Jeffrey Szer, Martin S Tallman, Daniel J Weisdorf
  [show abstract] [hide abstract]
  ABSTRACT: Background. Optimum post-remission treatment for acute myeloid leukemia in first complete remission remains uncertain. Previous comparisons of autologous versus allogeneic hematopoietic cell transplantation noted higher relapse, but lower treatment-related mortality though using bone marrow grafts with treatment-related mortality of 12-20%. Design and Methods. Recognizing lower treatment-related mortality using autologous peripheral blood grafts, in an analysis of registry data from the Center for International Blood and Transplant Research, we compared treatment related mortality, relapse, leukemia-free survival, and overall survival for acute myeloid leukemia in first complete remission (median ages 36-44, range 19-60) receiving myeloablative HLA-matched sibling donor (bone marrow, n=475 or peripheral blood, n=428) versus autologous peripheral blood (n=230). Results. Five year cumulative incidence of treatment-related mortality was 19 (95% confidence interval,16-23)%, 20(17-24)% and 8(5-12)% and relapse 20(17-24)% 26(21-30)% and 45(38-52)% for allogeneic bone marrow, allogeneic peripheral blood and autologous peripheral blood, respectively. At 5 years, leukemia-free survival and overall survival were similar: allogeneic bone marrow 61(56-65)% and 64(59-68)%; allogeneic peripheral blood 54(49-59)% and 59(54-64)%; autologous peripheral blood 47(40-54)% and 54(47-60)%; p=0.13 and 0.19, respectively. In multivariate analysis treatment-related mortality was lower after autologous peripheral blood versus allogeneic bone marrow / peripheral blood [relative risk 0.37(0.20-0.69); p=0.001], but treatment failure (death or relapse) after autologous peripheral blood was significantly more likely [relative risk 1.32(1.06-1.64); p=0.011]. Five year overall survival, however was similar in patients who received an autologous peripheral blood (n=230) [relative risk 1.23(0.98-1.55) p=0.071] or allogeneic bone marrow / peripheral blood (n=903). Conclusions. In the absence of a HLA-matched sibling donor, autologous peripheral blood may provide acceptable alternative post-remission therapy for acute myeloid leukemia first complete remission.
  Haematologica 09/2012; · 6.42 Impact Factor
• Article: Sister Mary Joseph nodule from prostate cancer.

  Kimberly Kruczek, Chadi Nabhan
  The Journal of the American Osteopathic Association 07/2012; 112(7):462.
• Article: The role of IMiDs alone or in combination in prostate cancer.

  Chadi Nabhan, Daniel P Petrylak
  [show abstract] [hide abstract]
  ABSTRACT: Recent insights into mechanisms by which prostate cancer becomes castration resistant have allowed better and more rational therapeutic design. These novel therapies have complemented the modest success that chemotherapy has shown in recent years changing the landscape of this disease and leading to improved outcomes. Angiogenesis and immune deregulation are 2 pathways that have increasingly been shown to lead into castration resistant prostate cancer (CRPC). Thalidmide and lenalidomide are immunomodulatory agents with antiangiogenesis properties that have shown activity in this setting with acceptable safety profile. In this review, we discuss briefly the different mechanisms that render prostate cancer castration resistant and elaborate on thalidomide and lenalidomide data in CRPC after reviewing their theoretic mechanisms of action. This timely review coincides with the identification of newer therapies against CRPC affirming our steady movement toward better disease control.
  Clinical Genitourinary Cancer 05/2012; 10(3):141-6. · 2.61 Impact Factor
• Article: Her wedding.

  Chadi Nabhan
  Journal of Clinical Oncology 04/2012; 30(21):2701-2. · 18.37 Impact Factor